9788419284365.Lenhan_Manual Washington de Cardiooncología

124

MANUAL WASHINGTON DE CARDIOONCOLOGÍA

22. ein K, Ball S, Zaw M, et al . Abstract P1-16-04: Risk of venous thromboembolism with abemaciclib based regimen versus other CDK 4/6 inhibitor containing regimens in pa tients with hormone receptor-positive HER2-negative metastatic breast cancer. Cancer Res . 2019;79(suppl 4):P1-16-04-P11-16-04. 23. Al-Samkari H, Leiva O, Dagogo-Jack I, et al . Impact of ALK rearrangement on venous and arterial thrombotic risk in NSCLC. J orac Oncol . 2020;15(9):1497-1506. 24.Alahmari AK, Almalki ZS, Alahmari AK, Guo JJ. romboembolic events associated with bevacizumab plus chemotherapy for patients with colorectal cancer: a meta-analysis of ran domized controlled trials. Am Health Drug Bene ts . 2016;9(4):221-232. 25.Munoz Martin AJ, Ramirez SP, Moran LO, et al . Pharmacological cancer treatment and venous thromboembolism risk. Eur Heart J Suppl . 2020;22(suppl C):C2-C14. 26.Petrelli F, Cabiddu M, Borgonovo K, Barni S. Risk of venous and arterial thromboembolic events associated with anti-EGFR agents: a meta-analysis of randomized clinical trials. Ann Oncol . 2012;23(7):1672-1679. 27.Barni S, Labianca R, Agnelli G, et al . Chemotherapy-associated thromboembolic risk in cancer outpatients and e ect of nadroparin thromboprophylaxis: results of a retrospective analysis of the PROTECHT study. J Transl Med . 2011;9:179. 28. Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood . 2008;111(10):4902-4907. 29. Seng S, Liu Z, Chiu SK, et al. Risk of venous thromboembolism in patients with cancer treated with Cisplatin: a systematic review and meta-analysis. J Clin Oncol . 2012;30(35):4416-4426. 30.Key NS, Khorana AA, Kuderer NM, et al . Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol . 2020;38(5):496-520. 31.Merli G, Spiro TE, Olsson CG, et al . Subcutaneous enoxaparin once or twice daily com pared with intravenous unfractionated heparin for treatment of venous thromboembolic disease. Ann Intern Med . 2001;134(3):191-202. 32. Prandoni P, Lensing AW, Piccioli A, et al . Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombo sis. Blood . 2002;100(10):3484-3488. 33.Lee AY, Levine MN, Baker RI, et al . Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med . 2003;349(2):146-153. 34.Raskob GE, van Es N, Verhamme P, et al . Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med . 2018;378(7):615-624. 35. Young AM, Marshall A, irlwall J, et al . Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol . 2018;36(20):2017-2023. 36. Agnelli G, Becattini C, Meyer G, et al . Apixaban for the treatment of venous thromboembo lism associated with cancer. N Engl J Med . 2020;382(17):1599-1607. 37. Mulder FI, Bosch FTM,Young AM, et al . Direct oral anticoagulants for cancer-associated venous thromboembolism: a systematic review and meta-analysis. Blood . 2020;136(12):1433-1441. 38. Khorana AA, Noble S, Lee AYY, et al . Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH. J romb Haemost . 2018;16(9):1891-1894.

Copyright © 2023 Wolters Kluwer, Inc. Unauthorized reproduction of the content is prohibited.